×
Biomea Fusion Total Liabilities 2020-2024 | BMEA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biomea Fusion total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Biomea Fusion Total Liabilities 2020-2024 | BMEA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biomea Fusion total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$150.5B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$115.4B
Gilead Sciences (GILD)
$109.4B
CSL (CSLLY)
$85.4B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$34.4B
Alnylam Pharmaceuticals (ALNY)
$30.2B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$22.6B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$18.3B
Moderna (MRNA)
$14.3B
Incyte (INCY)
$13.6B
Genmab (GMAB)
$13.6B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.8B
Vaxcyte (PCVX)
$10.9B
Bio-Techne Corp (TECH)
$10.5B
Sarepta Therapeutics (SRPT)
$10.2B
Exact Sciences (EXAS)
$10B
Exelixis (EXEL)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
QIAGEN (QGEN)
$9.3B
Intra-Cellular Therapies (ITCI)
$8.8B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$7.5B
Repligen (RGEN)
$7.2B